Aplevant 0.75mg Pre-filled Pen
Marketer
Lupin Ltd
Salt Composition
Dulaglutide (0.75mg)
Overview Aplevant 0.75mg Pre-filled Pen
In adults with type 2 diabetes, the Aplevant 0.75mg pre-filled pen, an injectable medication, reduces blood glucose. It stimulates insulin production and curbs hepatic glucose output. Dosage of the Aplevant 0.75mg pre-filled pen is individualized, factoring in your health status and other diabetes treatments. Administration is flexible, anytime daily, with or without food, but consistent weekly timing optimizes efficacy. Your healthcare provider will demonstrate proper injection technique. Strict adherence to instructions is crucial; discontinuation requires medical consultation to avoid dangerously elevated blood glucose. Effective blood sugar management necessitates combining Aplevant 0.75mg pre-filled pen with a healthy diet and exercise regimen. Refrigerate the Aplevant 0.75mg pre-filled pen (avoid freezing) until use. Common side effects include nausea, diarrhea, stomach upset, and decreased appetite. Hypoglycemia (low blood sugar) is possible, particularly with concomitant hypoglycemic agents; learn its recognition and management. Prior to commencing treatment, inform your doctor of any history of liver or kidney disease, pancreatitis, or gastrointestinal issues, and any concurrent medications. Consult your doctor regarding Aplevant 0.75mg pre-filled pen use during pregnancy or breastfeeding.
Uses of Aplevant 0.75mg Pre-filled Pen
Managing type 2 diabetes
Major Benefits of Aplevant 0.75mg Pre-filled Pen:
Your healthcare provider will instruct you on the proper administration of this medication.
Common Side effects of Aplevant 0.75mg Pre-filled Pen:
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Loss of appetite
How to use Aplevant 0.75mg Pre-filled Pen:
Your healthcare provider will instruct you on the proper administration of this medication.
How Aplevant 0.75mg Pre-filled Pen works:
Aplevant 0.75mg pre-filled pen is an antidiabetic drug that enhances insulin secretion from the pancreas, suppresses hyperglycemic hormones, retards gastric emptying, and mitigates appetite.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while using Aplevant 0.75mg Pre-filled Pen is not recommended due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The use of Aplevant 0.75mg Pre-filled Pen during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Patient consultation with their doctor is advised.
Breast feedingCONSULT YOUR DOCTOR
Data on Aplevant 0.75mg pre-filled pen use while breastfeeding is absent. Seek medical advice from your physician.
DrivingCONSULT YOUR DOCTOR
The impact of Aplevant 0.75mg Pre-filled Pen on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
The 0.75mg Aplevant pre-filled pen is considered safe for individuals with kidney disease; dose modification isn't necessary. Nevertheless, closely observe kidney function in patients with impaired renal capacity experiencing significant gastrointestinal side effects. Exercise prudence when administering the 0.75mg Aplevant pre-filled pen to patients exhibiting end-stage renal disease.
LiverSAFE IF PRESCRIBED
The use of the Aplevant 0.75mg pre-filled pen in patients with hepatic impairment is likely safe. Preliminary findings indicate dose modification may be unnecessary. Physician consultation is advised.
What if you forget to take Aplevant 0.75mg Pre-filled Pen :
Forgetting a dose of your Aplevant 0.75mg pre-filled pen? Administer it immediately upon recollection, unless your next scheduled dose falls within 72 hours; in that case, omit the missed dose. Avoid administering two Aplevant 0.75mg pre-filled pen doses within a 72-hour period.
Facts to Know About Aplevant 0.75mg Pre-filled Pen
| Label | Value |
|---|---|
| Chemical Type | GLP-1 Receptor Agonist |
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
| Actions | GLP-1 Receptor Agonists: Insulin-Stimulating Agents |




